{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreidpqcelvlcmhyllgja4j5njzw4qtf74ks4lgze47sv6rvywjcrhya",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mphy63zwqjf2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihfw7kwuhrzufvjebiiduwstlsk64r2h55ka62flg3fegeqxa6goy"
    },
    "mimeType": "image/jpeg",
    "size": 328580
  },
  "path": "/news/2026-06-kidney-cancer-gene-reveals-unexpected.html",
  "publishedAt": "2026-06-29T21:20:04.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "A common genetic mutation that helps some kidney cancers survive may also expose an unexpected weakness, one that MUSC Hollings Cancer Center researchers hope to transform into a new treatment strategy. In a study published in Cancer Research, Aguirre de Cubas, Ph.D., and colleagues have discovered that kidney cancer cells lacking the tumor suppressor gene SETD2 become highly dependent on a protein called BCL-xL for survival. By targeting that dependency, the researchers were able to selectively eliminate SETD2-deficient cancer cells in laboratory models while largely sparing cancer cells with intact SETD2. The findings identify a potential new therapeutic strategy for patients with a particularly aggressive subset of kidney cancers.",
  "title": "Kidney cancer gene reveals an unexpected weakness and a new path for treatment"
}